PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients

Tsang, Julia Y. S.; Au, Wai-Ling; Lo, Kwan-Yin; Ni, Yun‐Bi; Hlaing, Thazin; Hu, Jintao; Chan, Siu‐Ki; Chan, Kui-Fat; Cheung, Sai‐Yin; Tse, Gary M.

doi:10.1007/s10549-016-4095-2

Cited by 98 publications

(86 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PD‐L1 expression evaluated by IHC on untreated primary BC has been associated with both better and poorer clinical outcome. In particular, several authors reported poorer disease‐free survival (DFS)/recurrence‐free survival (RFS) and/or overall survival (OS) in cases of higher PD‐L1 expression on primary BC , especially in the TN subtype . These results seems to be consistent with the previously mentioned correlation between PD‐L1 expression and unfavorable clinicopathological BC features, thus possibly indicating that PD‐L1 expression may be part of the immune evasion process taking place in the context of tumor microenvironment .…”

Section: Methodssupporting

confidence: 77%

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple‐negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this appealing treatment strategy. In this context, the role of programmed cell death ligand 1 (PD‐L1) as a potential prognostic and/or predictive biomarker has been intensively explored, with controversial results. The aim of the present review is to collect available evidence on the biological relevance and clinical utility of PD‐L1 expression in BC, with particular emphasis on technical aspects, prognostic implications, and predictive value of this promising biomarker. Implications for Practice In the light of the promising results coming from trials of immune checkpoint inhibitors for breast cancer treatment, the potential predictive and/or prognostic role of programmed cell death ligand 1 (PD‐L1) in breast cancer has gained increasing interest. This review provides clinicians with an overview of the available clinical evidence regarding PD‐L1 as a biomarker in breast cancer, focusing on both data with a possible direct impact on clinic and methodological pitfalls that need to be addressed in order to optimize PD‐L1 implementation as a clinically useful tool for breast cancer management.

show abstract

Section: Methodssupporting

confidence: 77%

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

show abstract

“…In our present study, no markers, including PD‐1, expressed in TIMC were associated with prognosis. No apparent correlation between PD‐1 expression and prognosis was found in our study although previous studies have shown inconsistent results . In renal cell carcinoma, PD‐1 expression in TIMC was independently associated with poor outcome .…”

Section: Discussionmentioning

confidence: 99%

“…In renal cell carcinoma, PD‐1 expression in TIMC was independently associated with poor outcome . In glioblastoma and Her2 positive breast carcinoma, patients with PD‐L1 positive expression in tumor cell and PD‐1 low expression in TIMC showed worse prognosis . These results indicate that PD‐1 status may be variable in interaction with PD‐L1 status of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma

Satô

Akiba

Kawahara

et al. 2018

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…Some studies reporting no correlation of PD-L1 expression with survival [30,[33][34][35][36][37][38][39], others reporting worse survival [40,41], and some reporting better survival outcomes [36,37]. The association of PD-L1 expression with better overall survival seems counter-intuitive because PD-L1 on tumor cells interact with T cells leading to T cell inactivation and suppression of immunity; perhaps, higher PD-L1 expression is associated with higher levels of TILs, rending high levels of PD-L1 a favorable marker reflecting the strength of the anti-tumor immune response [22,38].…”

Section: Discussionmentioning

confidence: 99%

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: What is the Evidence?

Chok¹,

Chokr²

2018

J Neoplasm

View full text Add to dashboard Cite

Breast cancer is the most prevalent breast cancer in women. Despite our deeper understanding of mammary oncogenesis, 20% of breast cancer patients develop metastasis and die. There is a dire need for novel therapies especially for more aggressive subtypes like triple negative (TNBC) and HER2 positive breast cancers. For long, breast cancer was thought to be less immunogenic in nature compared to other solid malignancies like melanoma and non-small cell lung cancer, both later cancers yielding great results with immunotherapy. As we learn more about the role of tumor microenvironment in tumor occurrence, progression and response to therapy, there is growing evidence that TNBC is more immunogenic in nature compared to other breast cancers, which encouraged researchers to investigate its response to immune check point inhibitors. TNBC is characterized by a high level of immune cell infiltration including tumor infiltrating lymphocytes (TILs) which have been associated with better outcomes. The prognostic values of TILs and PD-L1 expression on tumor cells have been an area of interest and remain uncertain to date. The hope is that future trials will unravel more answers about the complex interaction between TILs and tumor cells in TNBC and help develop biomarkers to identify responders to checkpoint inhibitors. In this review, we discuss the immunogenic nature of TNBC, the clinical relevance of TILs and PD-L1 expression and the promising results of early phase trials of checkpoint blockade.

show abstract

PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients

Abstract: Our data showed the relevance of PD-L1 expression in HER2+ breast cancer. A combined evaluation of PD-L1 and PD-1 TIL in the prognosis of breast cancer might also be of value in treatment prediction.

Cited by 98 publications

References 42 publications

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: What is the Evidence?

Contact Info

Product

Resources

About